A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV).

Published: 11-07-2013
Last updated: 22-04-2024

To assess the efficacy, measured as progression free survival, and safety of Selumetinib in combination with docetaxel, compared to docetaxel alone, in patients receiving second line treatment for KRAS mutation-positive, locally advanced or...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Respiratory and mediastinal neoplasms malignant and unspecified
Study type	Interventional

Summary

ID

NL-OMON40580

Source
ToetsingOnline

Brief title
SELECT-1

Condition

- Respiratory and mediastinal neoplasms malignant and unspecified

Synonym
lung cancer, Non small cell lung cancer

Research involving
Human

Sponsors and support

Primary sponsor: Astra Zeneca
Source(s) of monetary or material Support: Opdrachtgever/sponsor AstraZeneca

Intervention

Keyword: Docetaxel, KRAS, Non Small Cell Lung Cancer, Selumetinib

Outcome measures

Primary outcome

Progression Free Survival (PFS)

Secondary outcome

- Overall survival (OS)

- Objective Response Rate (ORR)

- Duration of Response (DoR)

- To assess the effect on non small cell lung cancer symptoms

- Safety

- Tolerability

- To investigate the pharmacokinetics of Selumetinib and N-desmethyl

Selumetinib when administered in combination with docetaxel.

Study description

Background summary

Patients with advanced non-small cell lung cancer (NSCLC) have a very poor prognosis. Therefore, there is a strong medical need for medicines that have more benefit for the patient than the current standard treatment. Selumetinib (AZD6244) is a new agent that inhibits a protein called MEK. MEK is part of the RAS/RAF/MEK/ERK kinase cascade. This cascade plays a pivotal role in cell proliferation and survival. Over-activation of this pathway has been implicated in numerous cancers, including NSCLC with KRAS mutations.
Selumetinin can be effective as monotherapy or when given in combination with chemotherapy.
Pre-clinical experiments demonstrated that a KRAS mutation in a tumour leads to a better response on treatment with selumetinib in combination with chemotherapy compared to chemotherapy alone.
A previous clinical trial has shown that the combination of selumetinib with docetaxel provided potential clinical benefit as second-line therapy in patients with NSCLC.
Further studies are necessary to assess the efficacy and safety of Selumitinib in combination with docetaxel in patients with KRAS mutation-positive NSCLC.

Study objective

To assess the efficacy, measured as progression free survival, and safety of Selumetinib in combination with docetaxel, compared to docetaxel alone, in patients receiving second line treatment for KRAS mutation-positive, locally advanced or metastatic non small cell lung cancer.

Study design

Phase III, double-blind, randomised, placebo-controlled study
Randomised in a ratio of 1:1
- Selumetinib (75 mg dd on every day of a cycle of 21 days) in combination with 75 mg/m2 docetaxel (given on day 1 of every 21 day cycle)
- Placebo in combination with 75 mg/m2 docetaxel (given on day 1 of every 21 day cycle)

Intervention

Patient will be dosed twicedaily with a oral dose (capsules) of Selumetinib or placebo in combination with 75 mg/m2 docetaxel iv, administered on day 1 of each 21 day cycle.

Study burden and risks

On several days during the study patients will undergo the following assessments:
- anamnesis (at screening also medical history)
- physical examination
- WHO performance status
- vital signs (blood pressure, pulse)
- length
- weight
- CT or MRI scan
- ECG
- eye assessment
- blood and urine assessments
- MUGA/echocardiogram
- questionnaires (LSCC (specific voor lung cancer symptoms) en SF-36v2)
- pregnancy test

Adverse events of Selumetinib (AZD6244), docetaxel or the combination:
Adverse events that may be caused by Selumetinib are: diarrhea, nausea, vomiting, fever, difficulty breathing or shortness of breath, blurring of vision, decrease in the pumping performance of the heart, swelling of the face or extremities, rash, dry skin, nail changes, tiredness, increase in blood pressure, stomatitis, increase in phosphate level, increase in some liver proteins, low albumin level.
Adverse events, that probably may be caused by selumetinib are: weakness of neck muscles, cough, eye problems, increase in blood level of CPK.
The most common side effects that may be caused by docetaxel are: decrease in number of white blood cells, rash, diarrhea, nausea, vomiting, stomatitis, hair loss, tiredness, burning or tingling sensation in hands or feet, muscle pain, elevated tear production, allergic reaction and nail changes.
When selumetinib was used in combination with docetaxel, the number of patients with side effects, and or the severity of side effects was increased.
Female patients cannot become pregnant during this study.

Contacts

Public
Astra Zeneca

Louis Pasteurlaan 5
Zoetermeer 2719 EE
NL
Scientific
Astra Zeneca

Louis Pasteurlaan 5
Zoetermeer 2719 EE
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Provision of informed consent
* Male or female patients, aged at least 18 years
* Histological or cytological confirmation of locally advanced or metastatic non small cell lung cancer
* Failure of 1st line anti-cancer therapy (either to radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following 1st line therapy
* WHO Performance status 0-1
* Patients must be eligible to receive treatment with docetaxel
* At least one evaluable lesion
* KRAS mutation positive tumour sample
* Negative pregnancy test or postmenopausal
* Serum creatinin clearance >50 mL/min
* Patients should be able to swallow capsules
* Patient should be eligible to receive treatment with G-CSF
* Patients should be able to complete the PRO instruments

Exclusion criteria

- Mixed small cell and non-small cell lung cancer histology;- Received >1 prior anti-cancer drug regimen for advanced or metatstatic NSCLC;- Having received an investigational drug within 30 days of starting treatment or within five half-lives of the compound;- Receiving or have received systemic anti-cancer therapy within 4 weeks prior to starting study treatment

or any anticancer therapy which has not been cleared from the body by the time of starting treatment;- Prior treatment with a MEK inhibitor or any docetaxel-containing regimen;- Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids);- Laboratory values as listed below:
* ANC <1.5 x 109/L (1500 per mm3)
* Platelets <100 x 109/L (100.000 per mm3)
* Haemoglobin < 9.0 g/dL
* Serum bilirubin > 1.5 x Upper Limit of Normal
* AST or ALT in patients with no liver metastasis: >2.5 x ULN
* AST or ALT in patients with liver metastasis: >5 x ULN
* AST or ALT > 3.5 x ULN and <5 x ULN in patients with liver metastasis and ALP > 6 x ULN;- Cardiac conditions as follows:
* Uncontrolled hypertension (BP >150/95 mmHg)
* Acute coronary syndrome within 6 months prior to starting treatment
* Angina Canadian Cardiovascular Society grade II-IV
* Symptomatic heart failure
* Prior or current cardiomyopathy
* Baseline LVEF < 55% by echocardiography
* Several valvular heart disease
* Atrial fibrilation with a ventricular rate >100 bpm on ECG at rest;* Any evidence of severe uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant including hepatitis B, C and HIV;* Refractory nausea and vomiting, chronic gastrointestinal diseases or significant bowel resection that would preclude adequate absorption;- Ophthalmologic conditions:
* Current or past history of central serous retinopathy
* Current or past history of retinal vein occlusion
* Intraocular pressure > 21 mmHg or uncontrolled glaucoma

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	09-10-2013
Enrollment:	30
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	NA
Generic name:	Selumetinib
Product type:	Medicine
Brand name:	Taxotere
Generic name:	Docetaxel
Registration:	Yes - NL intended use

Ethics review

Approved WMO Date:	11-07-2013
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	10-09-2013
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	08-10-2013
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	15-10-2013

Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	12-05-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	03-10-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	24-10-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	11-11-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	13-05-2015
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	18-05-2015
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	10-07-2015
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO Date:	06-01-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	15-01-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	01-03-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	29-03-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	02-08-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	15-09-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	23-09-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2013-001676-38-NL
ClinicalTrials.gov	NCTnummerisnognietbekend.
CCMO	NL45179.031.13